ABSTRACT

Background: The Republic of Korea has a very low prevalence of human immunodeficiency virus (HIV) infection, but the number of new HIV diagnoses has steadily risen, strongly indicating a large number of undetected HIV infections. Thus, it is important for Korean public health authorities to adopt and encourage cost-effective HIV detection tools, such as rapid HIV screening tests. In this study, we aimed to evaluate the cost-effectiveness of enzyme-linked immunosorbent assays (ELISA) and rapid tests in a public health center (PHC) setting.

Methods: We developed a decision analytic model to assess the per-examinee cost and the cost-effectiveness of identifying HIV patients in a PHC setting using two HIV testing strategies: conventional HIV screening by ELISA versus rapid HIV testing. Analysis was performed in two scenarios: HIV testing in an average-risk population and in a high-risk population.

Results: Compared to the ELISA, the rapid test was cost-saving and cost-effective. The per-examinee cost was USD 1.61 with rapid testing versus USD 3.38 with ELISA in an average-risk population, and USD 4.77 with rapid testing versus USD 7.62 with ELISA in a high-risk population. The cost of identifying a previously undiagnosed HIV case was USD 26,974 with rapid testing versus USD 42,237 with ELISA in an average-risk population, and USD 153 with rapid testing versus USD 183 with ELISA in a high-risk population.

Conclusion: Rapid testing would be more cost-effective than using conventional ELISA testing for identifying previously undiagnosed HIV-infected cases in Korea, a country with extremely low HIV prevalence.

Keywords: HIV Screening Test; Cost-effectiveness Analysis; Korea

INTRODUCTION

Since its peak in 1997, the global incidence of human immunodeficiency virus (HIV) infection has decreased. However, in the Republic of Korea—where the prevalence of HIV/AIDS has been very low of 0.02% (10,000 of the total population) in contrast to 0.8% (36.7 million people) globally in 2016—the number of newly diagnosed HIV patients has continuously
Disclosure
The authors have no potential conflicts of interest to disclose.

Author Contributions
Conceptualization: Lee YH, Bang JH, Park SM, Kang CR. Formal analysis: Lee YH. Methodology: Lee YH, Park SM, Kang CR. Writing - original draft: Lee YH. Writing - review & editing: Bang JH, Park SM, Cho SI, Oh MD, Lee JK.

The majority of newly diagnosed HIV patients in Korea receive antiretroviral treatment (ART) and exhibit good compliance. Since patients with good treatment compliance rarely transmit HIV to others, the increasing number of HIV diagnoses in Korea may indicate a large population of undiagnosed HIV patients. Thus, it is important for Korean public health authorities to adopt and encourage cost-effective HIV detection tools.

Public health centers (PHCs) in Korea provide anonymous and free voluntary counseling and testing (VCT). The majority of PHCs use conventional HIV enzyme-linked immunosorbent assays (ELISA). However, PHCs in the metropolitan city of Seoul, as well as some regional PHCs outside of Seoul, have adopted rapid finger-stick HIV screening tests.

To our knowledge, no study has compared the cost-effectiveness of the rapid test versus the ELISA in a country with a very low HIV prevalence, such as Korea. Thus, in our present study we aimed to evaluate the cost-effectiveness of the two different HIV testing strategies in the PHC setting.

METHODS

Testing procedure
The ELISA HIV testing procedure involved phlebotomy, and submission of a serum specimen to a PHC laboratory for processing. Specimens with positive ELISA results were re-tested, and repeatedly reactive samples were subjected to confirmatory western blot analysis. If the second ELISA yielded negative results, no further analysis was performed. The examinee was notified of the results within 1 week via telephone.

Rapid HIV testing was performed using a finger-stick kit (SD BIOLINE HIV-1/2 3.0; Standard Diagnostics, Inc., Yongin, Korea). After blood sampling via finger-stick, the test result could be read within 20 minutes. Staff informed examinees of their results in a face-to-face meeting or via telephone. Examinees with positive rapid test results were asked to submit to ELISA testing. If ELISA results were positive, confirmatory western blot analysis was performed.

Examinees confirmed to have HIV infection were referred for further counseling at a PHC. Both the ELISA and rapid tests were performed anonymously and free of charge.

Strategies and scenarios
In Strategy 1, ELISA testing was performed to detect HIV in all examinees. In Strategy 2, HIV detection was performed by rapid testing using a finger-stick kit. Since the examinees’ risk level was unknown, analyses were performed in two different scenarios: one assuming that examinees belonged to an average-risk population, and the other assuming a high-risk population, such as men who have sex with men (MSM). In both scenarios, we determined the total cost of identifying a previously undiagnosed HIV infection in a PHC setting.

Decision tree
A decision tree model was developed to assess the cost-effectiveness of voluntary HIV testing at PHCs (Fig. 1). The decision tree structure represented both HIV testing strategies and both scenarios. Analyses were performed using TreeAge software (TreeAge Software Inc., Williamstown, MA, USA). For example, if a HIV-infected case underwent ELISA or rapid testing, the probability of a positive result being positive reflected the sensitivity, and the
The probability of it being negative would be 1 − sensitivity. Meanwhile, if a non-infected case underwent ELISA or rapid testing, the probability of the test result being negative would reflect the specificity, while the probability of it being positive would be 1 − specificity.

**Input variables**

Table 1 shows the input variables for each procedure. The listed baseline probabilities for estimating the cost per identified HIV-infected case using the two testing methods correspond to the chance nodes in Fig. 1. The HIV prevalence among the average-risk population in Korea was obtained from a UNAIDS report. The HIV prevalence among the high-risk population was acquired from a study of HIV infection global epidemiology among MSM in the Asia-Pacific region. Since there are no domestic reports on this subject, we assumed the test acceptance rate suggested by Farnham et al. The utilized sensitivities and specificities are as follows:

**Table 1. Summary of input parameters for the HIV testing cost-effectiveness analysis**

| Parameters                                           | Base value (range)                      | Ref. No. |
|------------------------------------------------------|----------------------------------------|----------|
| Probabilities that the examinee is HIV-infected       |                                        |          |
| Average-risk population                               | 0.0001 (0.00024–0.0004)                | 10       |
| Men who have sex with men                             | 0.052 (0.049–0.056)                    | 11       |
| Test acceptance rate                                  |                                        |          |
| ELISA                                                 | 0.80 (0.67–1.0)                        | 12       |
| Rapid test                                            | 0.80 (0.67–1.0)                        | 12       |
| Sensitivity and specificity of testing                |                                        |          |
| ELISA sensitivity                                     | 1.00 (0.977–1.0)                       | 13       |
| ELISA specificity                                     | 0.987 (0.981–1.0)                      | 14       |
| Confirmatory procedure (western blot) sensitivity      | 1.00                                   |          |
| Confirmatory procedure (western blot) specificity      | 1.00                                   |          |
| Rapid test sensitivity                                | 1.00 (0.992–1.0)                       | 22       |
| Rapid test specificity                                | 0.999 (0.992–1.0)                      | 22       |
| Acceptance rate of confirmatory test after rapid test | 0.747                                  | 15       |
| Cost, USD                                            |                                        |          |
| ELISA kit                                             | 4.2 (3.5–5.0)                          |          |
| Rapid test kit                                       | 2.0 (1.8–2.5)                          |          |
| Confirmatory procedure (western blot) test kit        | 98.0 (77.0–110.0)                      |          |

HIV = human immunodeficiency virus, ELISA = enzyme-linked immunosorbent assays.

*Conventional HIV screening test by enzyme immunoassay; *A confirmatory test procedure was assumed to have no false-positive or false-negative results, as is typically assumed in the literature; *Exchange rate: 1,000 KRW for one USD; *Data obtained by interviews with laboratory staff and test kit manufacturers.
and specificities of the ELISA, western blot, and rapid test, and the acceptance rate for the confirmatory test after the reactive rapid test, were found in the literature.\textsuperscript{13-15}

Our analysis included only additional costs. Fixed costs, such as wages, were not considered because the examinees’ choice of ELISA or rapid testing did not influence the monthly pay of the PHC staffs, or the number of laboratory technicians required. Costs were estimated from the provider perspective. All costs were reported in 2017 US dollars, assuming an exchange rate of KRW 1,000 for USD 1. The cost data for each HIV testing procedure—including the price of reagents, test kits, and laboratory supplies—were obtained from estimates provided by the test kit manufacturers and from the laboratory staff of the Seoul Research Institute of Public Health and Environment.

**Outcome measures**
Outcome measures were the average per-patient cost of completing the entire ELISA or rapid testing procedure, and the additional cost per identified and previously undiagnosed HIV-infected case. The latter was the key measure of cost-effectiveness, and was calculated by dividing the former average cost by the HIV infection detection rate per examinee. The detection rate was the product of HIV prevalence, the testing tool sensitivities, and the test acceptance rate.

**Sensitivity analysis**
Sensitivity analysis was performed using the input probabilities and cost variables that affected the cost per identified HIV-infected case. The HIV prevalence ranged 0.00024–0.0004 in the average-risk population, and 0.049–0.056 in the high-risk population. The acceptance rate for the ELISA and rapid test ranged 0.67–1.0, and the acceptance rate for western blot analysis after a reactive rapid test ranged 0.5–1.0. Test costs ranged from USD 3.5 to USD 5.0 for the ELISA, from USD 1.8 to USD 2.5 for the rapid test, and from USD 77.0 to USD 110.0 for the western blot kits.

**Ethics statement**
The present study protocol was reviewed and approved by Institutional Review Board (IRB) of Seoul National University (IRB No. E-1608-113-786).

**RESULTS**

**Average cost of the HIV testing procedure**
Table 2 summarizes the average costs per examinee completing the conventional ELISA and rapid test procedures. The average costs were higher for HIV-infected examinees than for uninfected examinees, since a positive result required confirmation with a second ELISA and western blot analysis. The overall average costs were consistently lower for the rapid testing procedure compared to ELISA because the rapid test kit was cheaper than the ELISA kit. The average per-examinee cost was USD 3.38 for ELISA and USD 1.61 for rapid testing in

| Strategies | Scenario 1: average-risk population | Scenario 2: high-risk population |
|------------|-----------------------------------|---------------------------------|
| Strategy 1: ELISA | USD 3.38 | USD 7.62 |
| Strategy 2: rapid test | USD 1.61 | USD 4.77 |

HIV = human immunodeficiency virus, ELISA = enzyme-linked immunosorbent assays.

*In 2017 dollars.*
scenario 1 (average-risk population), and USD 7.62 for ELISA and USD 4.77 for rapid testing in scenario 2 (high-risk population).

### Cost-effectiveness of HIV testing strategies

Table 3 presents data regarding the additional cost per newly identified HIV patient among all examinees, as well as the cost-effectiveness of the two scenarios. In scenario 1, the additional cost was USD 42,237 with ELISA and USD 26,974 with the rapid test. In scenario 2, the additional costs were USD 183 and USD 153, respectively.

### Sensitivity analysis

In scenario 1, the cost of the rapid test kit was the variable having the largest effect on the average cost per identified HIV-infected individual. One-way sensitivity analysis revealed that the rapid test’s cost-effectiveness was best at USD 24,292, with the lowest-priced rapid test (USD 1.80), and worst at USD 33,682, with the highest-priced rapid test (USD 2.50). On the other hand, the cost-effectiveness of the ELISA was consistently USD 42,237.

In scenario 2, the acceptance rate of ELISA testing after a reactive rapid test was the variable with the largest effect on cost-effectiveness. One-way sensitivity analysis revealed that the rapid test’s cost-effectiveness was best at USD 141 with the highest ELISA acceptance rate (100%), and worst at USD 179 with the lowest ELISA acceptance rate (50%). In contrast, the cost-effectiveness of ELISA was consistently USD 183. In both scenarios, the rapid test was more cost-effective than the ELISA.

In a setting with higher HIV prevalence, the costs would be increased for both strategies in both scenarios. However, the cost-effectiveness for detecting previously undiagnosed HIV cases would be improved due to the lower the additional cost per HIV patient detected. Likewise, in a lower prevalence setting, the cost-effectiveness would be decreased.

All sensitivity analyses indicated that the rapid test had a consistent cost advantage over the ELISA, with regards to both the average cost per-examinee and the additional cost per identified HIV-infected case.

### DISCUSSION

The results of the present study demonstrated that the rapid HIV test is less expensive and more cost-effective compared to the conventional ELISA, even in Korea, which has a very low HIV prevalence. The average per-examinee costs of the rapid test (USD 1.61 in scenario 1 and USD 4.77 in scenario 2) were less than half the costs of the ELISA (USD 3.38 in scenario 1 and USD 7.62 in scenario 2). Moreover, the additional cost per newly identified HIV case using the rapid test (USD 26,974 in scenario 1 and USD 153 in scenario 2) was lower than the additional cost with ELISA testing (USD 42,237 in scenario 1 and USD 183 in scenario 2).
No previous study has compared the cost and cost-effectiveness of the ELISA versus the rapid test in an anonymous voluntary screening setting. However, a study from the United States reports that the cost of HIV-infected cases receiving their test results was lower with rapid testing than with conventional ELISA. In that study, although the rapid test had a higher per-patient cost, the cost per HIV-infected patient receiving test results (i.e., the cost-effectiveness) was about 25% lower with the rapid test compared to ELISA.  

Since the rapid test results could be provided within 20 minutes, wider adoption of rapid testing could reduce barriers to testing, and increase the number of voluntary participants in HIV screening programs. Participants who chose the rapid test were also more likely to receive their test results than those who chose a conventional test. Overall, use of the rapid test could increase the detection of previously undiagnosed HIV infections. This is in agreement with the results of a pilot project implemented in Korea in 2014.

There are several challenges associated with conducting the rapid test. Notably, the rapid test may be inappropriate for patients in an early stage of HIV infection, as its window period is longer than that using the ELISA. Additionally, the test results may be affected by the skill level of the testing staff. Nevertheless, the rapid test is useful, having the advantages of greater cost-effectiveness and a higher acceptance rate.

Our present study had several limitations. Importantly, we lacked more detailed data—such as the HIV prevalence and acceptance rate for each HIV testing procedure—therefore, we cannot be certain that this study reflects the exact HIV-related environment in Korea. Furthermore, our analysis did not include fixed costs—such as laboratory staff wages, the cost per examinee completing the HIV testing procedure, or the cost of identifying each additional HIV-infected case—therefore, the results cannot be used to simulate the budget of any national HIV screening program. Despite these limitations, this is the first study to demonstrate the cost-effectiveness of a rapid HIV test compared to the conventional ELISA in a country with a very low HIV prevalence, in which voluntary and anonymous screening is being implemented.

In conclusion, our present results suggest that use of a rapid test rather than the conventional ELISA would save costs and confer greater cost-effectiveness for the identification of previously undiagnosed HIV-infected cases in Korea, where the HIV prevalence is extremely low. Based on these results, we propose widespread adoption of the rapid test in PHCs throughout Korea.

REFERENCES

1. Wang H, Wolock TM, Carter A, Nguyen G, Kyu HH, Gakidou E, et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. *Lancet HIV* 2016;3(8):e361-87. 
PUBMED | CROSSREF

2. Korea Centers for Diseases Control and Prevention. *The Status of HIV/AIDS Infection of Korea*. Cheongju: Korea Centers for Disease Control and Prevention; 2016.

3. Joint United Nations Programme on HIV/AIDS. *Global AIDS Update 2016*. Geneva: UNAIDS; 2016.

4. Choi JH, Kim S, Park P, Cho KS. *HIV/AIDS Notifications in Korea, 2016*. Cheongju: Korea Centers for Disease Control and Prevention; 2017.
5. Kim J, Lee E, Park BI, Bang JH, Lee JY. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009–2016: a nationwide study. Sci Rep 2018;8(1):3133. PUBMED | CROSSREF

6. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 2016;316(2):171-81. PUBMED | CROSSREF

7. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016;375(9):830-9. PUBMED | CROSSREF

8. Bavinton B, Grinsztejn B, Panuphak N, Jin F, Zablotska I, Prestage G, et al., editors. HIV treatment prevents HIV transmission in male serodiscordant couples in Australia, Thailand and Brazil. Proceedings of the 9th International AIDS Society Conference on HIV Science; 2017 July 23-26; Paris, France. Geneva: International AIDS Society; 2017.

9. Korea Centers for Disease Control and Prevention. HIV/AIDS Management Guidelines. Cheongju: Korea Centers for Disease Control and Prevention; 2015.

10. Joint United Nations Programme on HIV/AIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva: UNAIDS; 2013.

11. Beyrer C, Baral SD, van Griensven F, Goodreau SM, Charlebois ED, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012;380(9899):367-77. PUBMED | CROSSREF

12. Farnham PG, Hutchinson AB, Sansom SL, Branson BM. Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep 2008;123 Suppl 3:51-62. PUBMED | CROSSREF

13. U.S. Food and Drug Administration. Package Insert: Genetic Systems HIV-1/HIV-2 Plus O EIA. Silver Spring, MD: U.S. Food and Drug Administration; 2005.

14. Bulterys M, Jamieson DJ, O’Sullivan MJ, Cohen MH, Maupin R, Nesheim S, et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA 2004;292(2):219-23. PUBMED | CROSSREF

15. Kang CR, Bang JH, Cho SI, Kim KN, Lee HJ, Lee YH, et al. Implementing the use of rapid HIV tests in public health centers in Seoul: results of a pilot project, 2014. J Korean Med Sci 2016;31(3):467-9. PUBMED | CROSSREF

16. Kowalczyk Mullins TL, Braverman PK, Dorn LD, Kollar LM, Kahn JA. Adolescent preferences for human immunodeficiency virus testing methods and impact of rapid tests on receipt of results. J Adolesc Health 2010;46(2):162-8. PUBMED | CROSSREF

17. San Antonio-Gaddy M, Richardson-Moore A, Burstein GR, Newman DR, Branson BM, Birkhead GS. Rapid HIV antibody testing in the New York State anonymous HIV counseling and testing program: experience from the field. J Acquir Immune Defic Syndr 2006;43(4):446-50. PUBMED | CROSSREF

18. Keenan PA, Keenan JM. Rapid HIV testing in urban outreach: a strategy for improving posttest counseling rates. AIDS Educ Prev 2001;13(6):541-50. PUBMED | CROSSREF

19. Patel P, Bennett B, Sullivan T, Parker MM, Heffelfinger JD, Sullivan PS, et al. Rapid HIV screening: missed opportunities for HIV diagnosis and prevention. J Clin Virol 2012;54(1):42-7. PUBMED | CROSSREF

20. Gauthier-Dejean A, Bocobia J, Brunet S, Damond F, Plantier JC, Barin F. Performance of rapid tests for discrimination between HIV-1 and/or HIV-2 infections. J Med Virol 2015;87(12):2061-6. PUBMED | CROSSREF

21. Gilbert M. Impact and Use of Point of Care HIV Testing: a Public Health Evidence Paper. Vancouver, BC: BC Centre for Disease Control; 2007.

22. World Health Organization. HIV Assays: Operational Characteristics. Report 14. Simple/rapid Tests. Geneva: World Health Organization; 2004.